The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions
Open accessAbstract
We explored the relationship between ubiquitin proteasome system (UPS) and lysosomal markers and the formation of alpha-synuclein (alpha-syn) inclusions in nigral neurons in Parkinson disease (PD). Lysosome Associated Membrane Protein 1(LAMP1), Cathepsin D (CatD), and Heat Shock Protein73 (HSP73) immunoreactivity were significantly decreased within PD nigral neurons when compared to age-matched controls. This decrease was significantly greater in nigral neurons that contained alpha-syn inclusions. Immunoreactivity for 20S proteasome was similarly reduced in PD nigral neurons, but only in cells that contained inclusions. In aged control brains, there is staining for alpha-syn protein, but it is non-aggregated and there is no difference in LAMP1, CatD, HSP73 or 20S proteasome immunoreactivity between alpha-syn positive or negative neuromelanin-laden nigral neurons. Targeting over-expression of mutant human alpha-syn in the rat substantia nigra using viral vectors revealed that lysosomal and proteasomal markers were significantly decreased in the neurons that displayed alpha-syn-ir inclusions. These findings suggest that alpha-syn aggregation is a key feature associated with decline of proteasome and lysosome and support the hypothesis that cell degeneration in PD involves proteosomal and lysosomal dysfunction, impaired protein clearance, and protein accumulation and aggregation leading to cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
The roles of intracellular protein-degradation pathways in neurodegeneration
Rubinsztein, D. C. (2006) · Nature · doi:10.1038/nature05291 · Cited by 1,625
Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., & Yao, T.-P. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,524
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity
Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., & Björklund, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305623110 · Cited by 753
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission
Alvarez-Erviti, L., Seow, Y., Schapira, A. H., Gardiner, C., Sargent, I. L., Wood, M. J. A., & Cooper, J. M. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.029 · Cited by 748
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
“Such α-syn species are known to require the lysosome for its degradation [54], and lysosomal function has been reported to be decreased in PD patients [1, 11].”
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains
Alvarez-Erviti, L., Rodriguez-Oroz, M. C., Cooper, J. M., Caballero, C., Ferrer, I., Obeso, J. A., & Schapira, A. H. V. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.198 · Cited by 554
Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease
Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 553
Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., Singleton, A., Olanow, C. W., Merchant, K. M., Bezard, E., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00006-x · Cited by 529
Self-citationFighting neurodegeneration with rapamycin: mechanistic insights
Bové, J., Martínez-Vicente, M., & Vila, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3068 · Cited by 525
Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease
Guo, M., Wang, J., Zhao, Y., Feng, Y., Han, S., Dong, Q., Cui, M., & Tieu, K. (2020) · Brain · doi:10.1093/brain/awaa090 · Cited by 522
Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
John van Geest Centre for Brain Repair, D. O. C. N., Kouli, A., Torsney, K. M., Department of Medicine for the Elderly, C. U. H. N. F. T., Clinical Gerontology Unit, D. O. P. H. A. P. C., Kuan, W.-L., & John van Geest Centre for Brain Repair, D. O. C. N. (2018) · Parkinson’s Disease: Pathogenesis and Clinical Aspects · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 507
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475
Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases
Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S., & Kordower, J. H. (2012) · Movement Disorders · doi:10.1002/mds.25020 · Cited by 464
Self-citationAgeing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3039 · Cited by 449
Self-citationTunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes
Abounit, S., Bousset, L., Loria, F., Zhu, S., de Chaumont, F., Pieri, L., Olivo‐Marin, J., Melki, R., & Zurzolo, C. (2016) · The EMBO Journal · doi:10.15252/embj.201593411 · Cited by 414
Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
Challis, C., Hori, A., Sampson, T. R., Yoo, B. B., Challis, R. C., Hamilton, A. M., Mazmanian, S. K., Volpicelli-Daley, L. A., & Gradinaru, V. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0589-7 · Cited by 405
Review: Sporadic Parkinson's disease: development and distribution of α‐synuclein pathology
Del Tredici, K., & Braak, H. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12298 · Cited by 398
Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder?
Olanow, C. W., & Brundin, P. (2013) · Movement Disorders · doi:10.1002/mds.25373 · Cited by 390
Self-citationDehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M.-H., Doudnikoff, E., Vital, A., Vila, M., Klein, C., & Bezard, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112368109 · Cited by 379
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedOxidative stress in neurodegenerative diseases.
Chen, X., Guo, C., & Kong, J. (2012) · PubMed · doi:10.3969/j.issn.1673-5374.2012.05.009 · Cited by 356
Lysosomal impairment in Parkinson's disease
Dehay, B., Martinez‐Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., & Bezard, E. (2013) · Movement Disorders · doi:10.1002/mds.25462 · Cited by 340
Ferroptosis and cell death mechanisms in Parkinson's disease
Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 338
Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging
Plaza-Zabala, A., Sierra-Torre, V., & Sierra, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030598 · Cited by 323
Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease
Chu, Y., Morfini, G. A., Langhamer, L. B., He, Y., Brady, S. T., & Kordower, J. H. (2012) · Brain · doi:10.1093/brain/aws133 · Cited by 315
Self-citationMammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
Mitochondrial Biology and Parkinson's Disease
Perier, C., & Vila, M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009332 · Cited by 306
The hallmarks of Parkinson's disease
Antony, P. M. A., Diederich, N. J., Krüger, R., & Balling, R. (2013) · The FEBS Journal · doi:10.1111/febs.12335 · Cited by 300
α‐Synuclein oligomers and clinical implications for Parkinson disease
Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., & Lang, A. E. (2013) · Annals of Neurology · doi:10.1002/ana.23746 · Cited by 292
Freeman, D., Cedillos, R., Choyke, S., Lukic, Z., McGuire, K., Marvin, S., Burrage, A. M., Sudholt, S., Rana, A., O'Connor, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062143 · Cited by 289
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Moors, T. E., Hoozemans, J. J. M., Ingrassia, A., Beccari, T., Parnetti, L., Chartier-Harlin, M.-C., & van de Berg, W. D. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0154-3 · Cited by 278
Prying into the Prion Hypothesis for Parkinson's Disease
Brundin, P., & Melki, R. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1788-16.2017 · Cited by 275
Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map
Fujita, K. A., Ostaszewski, M., Matsuoka, Y., Ghosh, S., Glaab, E., Trefois, C., Crespo, I., Perumal, T. M., Jurkowski, W., Antony, P. M. A., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8489-4 · Cited by 273
Is Parkinson's disease a prion disorder?
Olanow, C. W., & Prusiner, S. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906759106 · Cited by 268
Self-citationAging and Parkinson's disease: Different sides of the same coin?
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2017) · Movement Disorders · doi:10.1002/mds.27037 · Cited by 268
Self-citationLee, E.-J., Woo, M.-S., Moon, P.-G., Baek, M.-C., Choi, I.-Y., Kim, W.-K., Junn, E., & Kim, H.-S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903480 · Cited by 267
Filomeni, G., Graziani, I., De Zio, D., Dini, L., Centonze, D., Rotilio, G., & Ciriolo, M. R. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.021 · Cited by 262
Autophagy and Alpha‐Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies
Xilouri, M., Brekk, O. R., & Stefanis, L. (2016) · Movement Disorders · doi:10.1002/mds.26477 · Cited by 261
Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins
Flavin, W. P., Bousset, L., Green, Z. C., Chu, Y., Skarpathiotis, S., Chaney, M. J., Kordower, J. H., Melki, R., & Campbell, E. M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1722-x · Cited by 258
Self-citationProtein degradation pathways in Parkinson’s disease: curse or blessing
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1004-6 · Cited by 253
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Henry, A. G., Aghamohammadzadeh, S., Samaroo, H., Chen, Y., Mou, K., Needle, E., & Hirst, W. D. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv314 · Cited by 235
Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons
Riessland, M., Kolisnyk, B., Kim, T. W., Cheng, J., Ni, J., Pearson, J. A., Park, E. J., Dam, K., Acehan, D., Ramos-Espiritu, L. S., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.08.013 · Cited by 180
“Other studies found evidence for dysfunctional lysosomes in the PD brain (Chu et al., 2009; van Dijk et al., 2013).”
BackgroundThe Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders
Vidoni, C., Follo, C., Savino, M., Melone, M. A. B., & Isidoro, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21394 · Cited by 164
Dilsizoglu Senol, A., Samarani, M., Syan, S., Guardia, C. M., Nonaka, T., Liv, N., Latour-Lambert, P., Hasegawa, M., Klumperman, J., Bonifacino, J. S., et al. (2021) · PLOS Biology · doi:10.1371/journal.pbio.3001287 · Cited by 134
Sardiello, M. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13131 · Cited by 135
Are there roles for brain cell senescence in aging and neurodegenerative disorders?
Tan, F. C. C., Hutchison, E. R., Eitan, E., & Mattson, M. P. (2014) · Biogerontology · doi:10.1007/s10522-014-9532-1 · Cited by 116
van Dijk, K. D., Persichetti, E., Chiasserini, D., Eusebi, P., Beccari, T., Calabresi, P., Berendse, H. W., Parnetti, L., & van de Berg, W. D. J. (2013) · Movement Disorders · doi:10.1002/mds.25495 · Cited by 101
Current disease modifying approaches to treat Parkinson’s disease
Lindholm, D., Mäkelä, J., Di Liberto, V., Mudò, G., Belluardo, N., Eriksson, O., & Saarma, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2101-1 · Cited by 99
BAX channel activity mediates lysosomal disruption linked to Parkinson disease
Bové, J., Martínez-Vicente, M., Dehay, B., Perier, C., Recasens, A., Bombrun, A., Antonsson, B., & Vila, M. (2014) · Autophagy · doi:10.4161/auto.28286 · Cited by 89
“Relevant to PD, activation of BAX, CASP9/caspase 9 and CASP3 have been observed in PD patients.(2,3,6,14-16) Supporting a pathogenic role for BAX in PD-related neurodegeneration, genetic ablation of BAX in mutant mice completely abrogates MPTP-induced dopaminergic cell death.”
BackgroundTorra, A., Parent, A., Cuadros, T., Rodríguez-Galván, B., Ruiz-Bronchal, E., Ballabio, A., Bortolozzi, A., Vila, M., & Bové, J. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.022 · Cited by 88
Malfertheiner, K., Stefanova, N., & Heras-Garvin, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.737195 · Cited by 46
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
Hunn, B. H. M., Vingill, S., Threlfell, S., Alegre-Abarrategui, J., Magdelyns, M., Deltheil, T., Bengoa-Vergniory, N., Oliver, P. L., Cioroch, M., Doig, N. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.029 · Cited by 38
What lysosomes actually tell us about Parkinson’s disease?
Bourdenx, M., & Dehay, B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.008 · Cited by 26
Cosden, M., Jinn, S., Yao, L., Gretzula, C. A., Kandebo, M., Toolan, D., Hatcher, N. G., Ma, L., Lemaire, W., Adam, G. C., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105507 · Cited by 23
Epothilone D inhibits microglia-mediated spread of alpha-synuclein aggregates
Valdinocci, D., Grant, G. D., Dickson, T. C., & Pountney, D. L. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.04.006 · Cited by 20
Guo, X., Tang, P., Hou, C., Chong, L., Zhang, X., Liu, P., Chen, L., Liu, Y., Zhang, L., & Li, R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.875101 · Cited by 19
TFE3-Mediated Autophagy is Involved in Dopaminergic Neurodegeneration in Parkinson’s Disease
He, X., Xie, Y., Zheng, Q., Zhang, Z., Ma, S., Li, J., Li, M., & Huang, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761773 · Cited by 16
Metadata
- Authors
- Chu, Y., Dodiya, H., Aebischer, P., Olanow, C. W., & Kordower, J. H.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 35
- Issue
- 3
- Pages
- 385-398
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2114723455
- Cited by
- 421
- References
- 62
- FWCI
- 13.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.